
SCOHIA PHARMA, Inc.



Target: SCOHIA PHARMA, Inc.

Business Outline: Research and development for renal, metabolic and cardiovascular related medicines

Total Investment: 10 billion JPY (INCJ 70.5%, Takeda 19.5%, MEDIPAL HD 10.0%)





Licensing of R&D products



Contribution to the development of a bio-venture ecosystem through creation of a large-scale Biotech

support

- •Promotion of domestic pharmaceutical companies' business portfolio conversion and opportunities to enhance international competitiveness
- •Realize drug-discovery technology and development products hidden inside pharmaceutical companies as a strategy conversion and promote open innovation through strengthening external cooperation